Dietary intake of nutrients involved in one-carbon metabolism and risk of urothelial cell carcinoma: A prospective cohort study

Pierre-Antoine Dugué, Maree T. Brinkman, Allison M. Hodge, Julie K. Bassett, Damien Bolton, Anthony Longano, John L. Hopper, Melissa C. Southey, Dallas R. English, Roger L. Mline and Graham G. Giles

Introduction

Urothelial cell carcinoma (UCC) includes tumors of the renal pelvis, the ureter, urinary bladder and proximal urethra, with about 90% of these originating in the urothelium of the bladder. While age, sex, smoking and occupational exposure to chemicals are established risk factors for the development of UCC, the role of dietary factors remains unclear.

Although it is biologically plausible that dietary factors are involved in the etiology of UCC due to their opportunity for contact with the urothelium, the World Cancer Research Fund’s (WCRF) Second Expert Report in 2007 found that the evidence was too limited to conclude that any food or nutrient was directly associated with the risk of bladder cancer, but limited evidence was identified suggesting that consumption of folate and milk, rich in vitamin B2 and B12, are associated with reduced risk, and drinking water contaminated with arsenic is associated with increased risk of developing bladder cancer. Similar conclusions were reached by the 2015 WCRF Systematic Literature Review Continuous Update Project Report. Folate (vitamin B9), which is one of several B group vitamins that are water-soluble and excreted via the urinary tract, may modify arsenic metabolism.

B-group vitamins such as folate and vitamins B2, B6 and B12 are present in a wide range of foods such as cereals, meat, fruit and vegetables and are involved in key cellular functions such as the metabolism of energy providing macronutrients. These vitamins also form part of the one-carbon metabolism.
What’s new?
Changes in DNA methylation are associated with an increased risk of urothelial-cell carcinoma (UCC). Because B vitamins and methionine play key roles in DNA synthesis, methylation and repair, they might also influence carcinogenesis. In this prospective study, however, the authors found no evidence that intake of these nutrients affects a patient’s risk of developing UCC, either positively or negatively. They also found no association with tumor aggressiveness nor with risk in the presence of other risk factors such as smoking or alcohol use.

Pathway and, as such, play a key role in DNA synthesis, repair and methylation, and therefore potentially influence carcinogenesis.11 In a recent study, we found that global DNA methylation was differentially associated with risk of UCC subtypes.12 While there is mounting evidence of a role for these key nutrients in the development of tumors at other sites, the few studies that have investigated associations between B vitamins and risk of UCC have been heterogeneous in design, measures, analyses and findings.13–17

A 2014 meta-analysis reported a potential inverse association between folate intake and bladder cancer risk, although this association was only evident from retrospective studies and not in prospective studies.18 One large US case-control study included in the meta-analysis which found no association of bladder cancer risk with folate intake, identified a potential inverse association with vitamin B12 intake.19

Our principal aim was to investigate prospectively associations between dietary intake of B-group vitamins and methionine and the risk of developing UCC, using a cohort of ethnically diverse, middle-aged individuals. Our secondary aims were to examine potential differences in risk between superficial and invasive disease and to assess whether associations were more evident for higher-risk groups such as smokers and alcohol drinkers, as these behaviors may alter nutritional status.

Material and Methods

Study sample
The Melbourne Collaborative Cohort Study (MCCS) is a prospective study of 41,513 participants (17,045 men) recruited between 1990 and 1994, 99.3% of whom were aged between 40 and 69 years at baseline.20 Study participants were recruited from the metropolitan area of Melbourne in Victoria, Australia. People of Southern European descent (born in Italy or Greece) were oversampled to extend the range of lifestyle exposures, including dietary habits. All study participants provided informed consent in accordance with the Declaration of Helsinki. The study was approved by Cancer Council Victoria’s Human Research Ethics Committee.

Case ascertainment
Cases of UCC were identified by record linkage with the Victorian Cancer Registry, which receives mandatory notification of all new cancer cases in Victoria, Australia, and the Australian Cancer Database. Incident UCC cases were identified up to 31 December 2015, using ICD-O-3 morphology codes 8120, 8122, 8130 or 8131. Diagnostic pathology reports were reviewed and classified according to the International Classification of Disease (ICD-O-3 WHO classification). Disease subtypes were defined according to behavior, with invasive UCC including any tumor that had penetrated or invaded the basement membrane. Superficial UCC included papillary transitional/urothelial cell neoplasm of low malignant potential (PUNLMP) or carcinoma in situ (CIS) that was completely confined within the epithelium.21 Cases with uncertain behavior type, including PUNLMP, and with a topography code corresponding to vagina (ICD-4: C52.9) were censored at the time of diagnosis. The remaining cases included topographic codes (ICD-O-3) corresponding to the bladder (C67), the kidney (C64-C65), the ureter (C66) and the urethra (C68).

Exclusion criteria
We excluded from the analysis participants who were diagnosed with UCC before study entry (N = 69). To avoid misclassification of dietary habits, we also excluded individuals who reported a personal history of stroke, heart disease, angina or diabetes at study entry as they may have changed their diet in response to their diagnoses (N = 3,793). Participants in the first and 99th percentile of the sex-specific energy intake distributions were also excluded, as they may represent aberrant reporting of food habits (N = 725); that is, males with energy intakes of <3,770 or >25,372 kcal/day, and females with energy intakes of <3,142 or >21,380 kcal/day. Finally, we excluded participants with missing dietary data (N = 38). Missing data (<1% in any of the other variables) were imputed with the median (for continuous variables) or mode (for categorical variables) of observed values of the corresponding variable.

Dietary intake estimates
Dietary information was obtained from a food frequency questionnaire (FFQ) specifically developed for the MCCS.22 This FFQ estimates the intake of 121 food items including meats, fish, fruits, vegetables, cereal-based foods, fats and oils, and both alcoholic and non-alcoholic beverages. Dietary measures for the B vitamins and methionine were derived from the Australian NUTTAB nutritional 2006 database.23 Mean daily intakes for nine nutrients (thiamine (B1), riboflavin (B2), niacin (B3), pantothenic acid (B5), vitamin B6, biotin (B8), folate (B9), vitamin B12 and methionine) were estimated by multiplying the daily frequency of each food item...
by the nutrient composition for an average sex-specific portion size.\textsuperscript{24–27} Folate intake was estimated using only that occurring naturally in food, as folate fortification was rare in Australia at the time baseline measures were collected. Intakes of energy and each nutrient were log transformed to obtain distributions closer to Gaussian, as these may provide a better model fit. Nutrient intakes were adjusted for energy using the residuals method.\textsuperscript{28} We calculated the Mediterranean diet score (MDS) as a measure of overall diet quality, which we have previously shown to be associated with invasive UCC risk.\textsuperscript{3} Using other dietary scores made virtually no difference to the results.

**Questionnaire and anthropometric measures**

Extensive data were also collected at recruitment on a wide range of exposures such as smoking, anthropometry (height, weight, waist and hip circumferences measured by trained staff using standard methods), alcoholic beverage intake, multivitamin use, country of birth, socioeconomic status (score ranging from 1 to 10 representing deciles of relative socioeconomic disadvantage of area of residence),\textsuperscript{29} highest level of educational attainment and physical activity.\textsuperscript{30}

**Statistical analysis**

Follow-up began at study entry and continued until date of diagnosis of UCC, date of diagnosis of cancer of an unknown primary site, date of an unconfirmed UCC or a tumor with uncertain behavior, date of death, date last known to be in Australia, or 31 December 2015, whichever came first.

Cox regression models were fitted, with age as the time axis,\textsuperscript{31} to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for UCC risk associated with each nutrient measure. For each nutrient, the proportional hazards assumption was assessed by test and visual inspection of the Schoenfeld residuals;\textsuperscript{22} these showed no violation of the assumption for any nutrient variable (Supporting Information). For each energy-adjusted nutrient, sex-specific quartiles were obtained using the whole sample and analyzed using the lowest quartile as the reference category. Departure from linearity in the relationship between B-group vitamins and UCC risk (overall, invasive and superficial) was investigated using likelihood ratio tests to compare models including dietary intake variables as linear versus categorical (using quartiles). If the relationship was found not to be linear, we tested for potentially U-shaped or bell-shaped relationship by adding a quadratic term to the model, which we tested using a likelihood ratio test. HRs were given per one standard deviation (SD) increase in each log-transformed nutrient variable to minimize the influence of very large values on the natural scale. Results for the raw variables of nutrient intakes showed similar results and were presented in Supporting Information.

Based on directed acyclic graphs,\textsuperscript{33} we fitted two models. Model 1 adjusted for the main potential confounders: sex, country of birth (Australia/New-Zealand, Southern Europe, Northern Europe), educational attainment (completed primary school or lower, some high or technical school, completed high or technical school, completed tertiary degree or diploma), socioeconomic status (decile categories fit as a continuous variable), smoking status (never, former: quit ≤15 years prior, former: quit >15 years prior, current ≤20 cigarettes per day, current >20 cigarettes per day) and alcohol intake (Australian NHMRC recommendations: none, 1–39 g/day [males] and 1–19 g/day [females], 40–59 g/day [males] and 20–39 g/day [females], 60+ g/day [males] and 40+ g/day [females]). Model 2 additionally adjusted for waist circumference (continuous), physical activity score (continuous), MDS (continuous), red meat intake (continuous) and reported intake of nonsteroidal anti-inflammatory drugs (NSAIDs) (none, aspirin only, other NSAIDs only, aspirin and other NSAIDs).

To test for heterogeneity in the HRs by tumor subtype (invasive vs. superficial), we fitted Cox proportional hazard regression models for competing risk using a data duplication method.\textsuperscript{34} To examine the interaction of intake of each nutrient with alcohol and smoking, both of which may affect the assimilation of vitamins, alcohol intake was categorized as never/low/high (>40 g/day for men and >20 g/day for women) and smoking as current/former/never.

Finally, we conducted a sensitivity analysis excluding participants who reported using multivitamin tablets, as these may contain B vitamins for which intake could not be assessed.

**Results**

We included 36,882 participants in the analysis, followed for a median time of 22.2 years. In total, 500 UCC cases were diagnosed (89% originating in the bladder, 7% in the kidney, 3% in the ureter, and 1% in the urethra), including 279 superficial and 221 invasive cases. Cases were more likely to be males from Southern Europe, smokers, alcohol drinkers and have higher BMI (Table 1). Spearman correlations between nutrient intakes are presented in Table 2. Moderate strong correlations (\(\rho \approx 0.5 \text{ to } 0.7\)) were observed for vitamin B12 with vitamin B6 and methionine, for folate with biotin, for thiamine with riboflavin, for vitamin B5 and B6, for vitamin B5 and B12 and for riboflavin and niacin.

We did not observe significant linear associations between intakes of B-group vitamins or methionine (on the log scale) and the risk of UCC, either in the basic or in the more comprehensive model (Table 3). The association appeared to be non-linear for the intake of vitamin B6 (departure from linearity \(p = 0.004\)), and there was evidence of an inverse U-shaped relationship (quadratic term \(p = 0.01\), not shown). Moderate intakes of vitamin B6 appeared to be associated with higher risk (quartile 2 vs. quartile 1: \(HR = 1.41\) [95% CI: 1.09–1.82], quartile 3 vs. quartile 1: \(HR = 1.47\) [95% CI: 1.13–1.91], quartile 4 vs. quartile 1: \(HR = 1.16\) [95% CI: 0.88–1.53]). Results from Model 1 and Model 2 were very similar, indicating that confounding was unlikely to play a role in any of the observed associations (Table 3). There was no evidence that
Table 1. Participants’ characteristics at baseline (1990–1994), N = 36,882

|                        | Cases (N = 500) | Non-cases (N = 36,382) |
|------------------------|-----------------|------------------------|
| Age at baseline        | Median [IQR]    | 61.4 [54.7–65.9]       | 54.7 [47.1–62.2]       |
| Sex                    | Male (%)        | 371 (74%)              | 14,150 (39%)           |
| Country of birth       | Australia, NZ, other | 313 (63%)              | 25,458 (70%)           |
|                        | Northern Europe | 36 (7%)                | 2,348 (6%)             |
|                        | Southern Europe | 151 (30%)              | 8,576 (24%)            |
| Education              | Primary school  | 126 (25%)              | 6,531 (18%)            |
|                        | Some high/technical school | 170 (34%)              | 13,912 (38%)           |
|                        | Completed high/technical school | 108 (22%)              | 7,559 (21%)            |
|                        | Degree/diploma  | 96 (19%)               | 8,380 (23%)            |
| SEIFA^1 score          | Median [IQR]    | 6 (3–8)                | 6 (3–9)                |
| Smoking                | Never           | 171 (34%)              | 21,487 (59%)           |
|                        | Former quit >15 years | 132 (26%)              | 5,135 (14%)            |
|                        | Former quit ≤15 years | 111 (22%)              | 5,771 (16%)            |
|                        | Current <20 cig/day | 33 (7%)                | 1,875 (5%)             |
|                        | Current >20 cig/day | 53 (11%)               | 2,114 (6%)             |
| Alcohol consumption    | 0               | 117 (23%)              | 11,518 (32%)           |
|                        | 1–39 g/day (M), 1–19 g/day (F) | 287 (57%)              | 20,050 (55%)           |
|                        | 40–59 g/day (M), 20–39 g/day (F) | 54 (11%)               | 3,243 (9%)             |
|                        | 60+ g/day (M), 40+ g/day (F) | 42 (8%)                | 1,571 (4%)             |
| Physical activity score| Median [IQR]    | 4 [1.5–5.5]            | 4 [1.5–5.5]            |
| BMI                    | Median [IQR]    | 26.9 [23.7–29.1]       | 26.2 [24.6–29.7]       |
| Waist circumference    | Median [IQR]    | 92.0 [84.4–99.1]       | 84.3 [75.0–93.5]       |
| MDS                    | Median [IQR]    | 5 [4–6]                | 5 [4–6]                |
| Thiamine (B1) (in mg/day) | Median [IQR] | 2.1 [1.7–2.4]          | 2.1 [1.7–2.4]          |
| RDI: 1.2 mg/day (M); 1.1 mg/day (F) |                                     |                        |
| Riboflavin (B2) (in mg/day) | Median [IQR] | 2.2 [1.9–2.7]          | 2.4 [2.0–2.9]          |
| RDI: 1.3 mg/day (M); 1.1 mg/day (F) |                                     |                        |
| Niacin (B3) (in mg/day) | Median [IQR]    | 30.3 [25.3–36.1]       | 30.3 [24.9–36.3]       |
| RDI: 16 mg/day (M); 14 mg/day (F) |                                     |                        |
| Pantothenic acid (B5) (in mg/day) | Median [IQR] | 4.2 [3.7–5.0]          | 4.2 [3.7–5.0]          |
| At: 6 mg/day (M); 4 mg/day (F) |                                     |                        |
| Vitamin B6 (in mg/day) | Median [IQR]    | 2.0 [1.7–2.5]          | 1.9 [1.6–2.5]          |
| RDI: 1.3 to 1.7 mg/day (M); 1.3 to 1.5 mg/day (F) |                                     |                        |
| Biotin (B8) (in µg/day) | Median [IQR]    | 44.8 [39.3–51.9]       | 45.7 [39.6–52.8]       |
| At: 30 µg/day (M); 25 µg/day (F) |                                     |                        |
| Folate (B9) (in µg/day) | Median [IQR]    | 297 [241–363]          | 314 [257–377]          |
| RDI: 400 µg/day (M); 400 µg/day (F) |                                     |                        |
| Vitamin B12 (in µg/day) | Median [IQR]    | 3.3 [2.5–4.2]          | 3.0 [2.3–4.1]          |
| RDI: 2.4 µg/day (M); 2.4 µg/day (F) |                                     |                        |
| Methionine (in mg/day) | Median [IQR]    | 1,664 [1,418–1,912]    | 1,612 [1,384–1,879]    |
| Tumor subtype          | Invasive        | 221 (44%)              | 221 (44%)              |
|                        | Superficial     | 279 (56%)              | 279 (56%)              |
| Tumor site (ICD-O-3 code) | Bladder (C67) | 443 (89%)              | 443 (89%)              |
|                        | Kidney (C64–C65) | 37 (7%)                | 37 (7%)                |
|                        | Ureter (C66)    | 14 (3%)                | 14 (3%)                |
|                        | Urethra (C68)   | 6 (1%)                 | 6 (1%)                 |
| Age at diagnosis       | Median [IQR]    | 74.4 [67.5–79.4]       | 74.4 [67.5–79.4]       |

^1SEIFA: socioeconomic indexes for area, index ranging from 1 to 10 representing relative socioeconomic disadvantage of area of residence. 29

Abbreviations: RDI: recommended dietary intake; M: males; F: females; AI: adequate intake; M: males; F: females.
intakes of B vitamins or methionine were differentially associated with risk of invasive or superficial UCC subtype (Table 4, for all nutrients: p heterogeneity >0.1).

In Table 5, we present results for potential effect modification by smoking and alcohol drinking status, as these may affect the metabolism of B vitamins. With the exception of thiamine, for which there was weak evidence of an inverse association with UCC risk for never drinkers (p heterogeneity = 0.02), we did not find that smoking or alcohol consumption modified the association between B-group vitamin or methionine intakes and UCC risk. No heterogeneity in the associations was observed by sex or country of birth either (data not shown).

Finally, we conducted the same analyses after excluding 6,184 (17%) participants who reported using multivitamin tablets, and similar findings were obtained (data not shown).

**Discussion**

We did not find evidence that dietary intake of any B-group vitamin or methionine, as estimated using a 121-item FFQ, was associated with the risk of UCC. The quadratic association we observed for vitamin B6 intake is difficult to interpret because both low and high intakes were associated with a lower risk of UCC (thus intermediary intakes associated with increased risk). There was no consistent evidence of effect heterogeneity across UCC subtypes, or within participant subgroups. That is, there did not appear to be a more protective effect of B vitamin intakes among higher-risk individuals such as smokers or alcohol drinkers as hypothesized. We did observe an interaction between alcohol drinking status and vitamin B1; an inverse association with UCC was observed in never drinkers. This association did not appear to have a clear explanation as we hypothesized that B vitamin intakes would be more beneficial in participants whose absorption of B vitamins may have deteriorated due to smoking or alcohol drinking.\(^{35,36}\) Given the number of tests performed in our study, we therefore conclude that the few and inconsistent tests with \(p < 0.05\) we observed were likely due to chance and require confirmation by other studies.

The main strength of our study is that it was prospective, thus minimizing the possibility of recall and selection biases. We had lengthy and virtually complete follow-up since the identification of incident UCC cases was performed by record linkage to Australian population-based cancer registries that have virtually complete coverage of the cohort participants. Although UCC is not a common cancer, we could include in our analysis a relatively large number of cases (\(N = 500\)), with information on tumor behavior. We also had extensive data on participant characteristics, which we used to produce less confounded estimates of association.

The main limitation of our analysis pertains to the use of a single FFQ administered at baseline to examine the risk of UCC over more than two decades: first, measurement error is considered to be large in FFQ-assessed dietary intakes, as we observed in our study,\(^{37}\) and this generally tends to attenuate measures of association;\(^{38}\) second, participants may have changed their diets substantially over two decades. These sources of measurement error are likely to have substantially reduced the power of our study. Additionally, we did not formally adjust our results for multiple testing because tests were largely non-independent in our study, but rather interpreted the few and inconsistent tests with \(p < 0.05\) as potential chance findings. We used food composition data for B vitamins and methionine from 2006 to apply to dietary data collected in the early 1990s. The mandatory fortification of bread flour with folate was not introduced until 2009 and voluntary fortification of flour and cereals was not permitted until June 1995;\(^{39}\) however, mandatory fortification of bread flour with thiamine was introduced from January 1st 1991;\(^{40}\) so levels assumed for FFQs completed early on may be overestimated. B vitamins have also been added to breakfast cereals in amounts determined by manufacturers and probably did not change systematically between 1990 and 2006. We were also not able to assess possible genetic influences such as variants in the *MTHFR* and *MTR* genes, which play a key role in DNA methylation processes and may substantially affect plasma concentrations of B vitamins.\(^{41}\) It has been suggested that extra folate will be required by individuals with the CT or TT genotypes of the *MTHFR* polymorphism,\(^{42}\) hence dietary intake is likely to be less important to people with the CC genotype and combining the genotypes may hide any association. Other associations between genetic loci

---

**Table 2. Spearman correlations between log-transformed intakes of B group vitamins and methionine**

| Vitamin B12 | Methionine |
|-------------|------------|
| Vitamin B6  | 0.14       | 0.07     |
| Folate (B9) | 0.56       | 0.02     |
| Biotin (B8) | 0.56       | 0.02     |
| Pantothenic acid (B5) | 0.14       | 0.07     |
| Niacin (B3) | 0.56       | 0.02     |
| Thiamine (B1) | 0.14       | 0.07     |

---

**References**

1. Spearman Correlations between Log-Transformed Intakes of B Group Vitamins and Methionine... Int. J. Cancer: 143, 298–306 (2018) © 2018 UICC
Table 3. Associations between log-transformed intakes of B group vitamins and methionine intake with the risk of UCC (N = 500)

| Vitamin          | Quartiles (mg/day) | Q1 [0.5–1.7] | Q2 [1.7–2.1] | Q3 [2.1–2.4] | Q4 [2.4–10.4] | Test for trend | p  |
|------------------|--------------------|--------------|--------------|--------------|--------------|---------------|-----|
| Thiamine (B1)    | Ref                | 0.94         | 0.73–1.21    | 0.64         | 0.95         | 0.74–1.22     | 0.68|
|                  |                    | 1.05         | 0.82–1.35    | 0.67         | 1.06         | 0.83–1.36     | 0.64|
|                  |                    | 0.98         | 0.76–1.27    | 0.88         | 0.98         | 0.76–1.27     | 0.90|
|                  | Test for trend     | p = 0.89     | p = 0.89     | p = 0.89     | p = 0.89     | p = 0.89      |     |
| Linear model     | Ref                | 0.99         | 0.91–1.09    | 0.87         | 0.99         | 0.91–1.09     | 0.89|
| Riboflavin (B2)  | Q1 [0.6–2.0]       | 1.14         | 0.90–1.46    | 0.27         | 1.16         | 0.91–1.48     | 0.22|
|                  | Q2 [2.0–2.4]       | 0.89         | 0.68–1.17    | 0.40         | 0.90         | 0.69–1.18     | 0.46|
|                  | Q3 [2.4–2.9]       | 1.00         | 0.76–1.31    | 0.98         | 1.00         | 0.76–1.31     | 0.99|
|                  | Test for trend     | p = 0.58     | p = 0.59     | p = 0.59     | p = 0.59     | p = 0.59      |     |
| Linear model     | Q1 [0.6–2.0]       | 1.01         | 0.91–1.11    | 0.91         | 1.01         | 0.92–1.11     | 0.86|
| Niacin (B3)      | Q1 [7.2–24.9]      | 0.91         | 0.71–1.17    | 0.46         | 0.92         | 0.72–1.18     | 0.51|
|                  | Q2 [24.9–30.3]     | 0.98         | 0.76–1.24    | 0.84         | 0.99         | 0.77–1.27     | 0.94|
|                  | Q3 [30.3–36.3]     | 0.93         | 0.72–1.19    | 0.55         | 0.94         | 0.73–1.21     | 0.63|
|                  | Test for trend     | p = 0.69     | p = 0.77     | p = 0.69     | p = 0.77     | p = 0.77      |     |
| Linear model     | Q1 [0.6–2.0]       | 0.99         | 0.90–1.09    | 0.88         | 1.00         | 0.91–1.10     | 0.98|
| Pantothenic acid (B5) | Q1 [1.3–3.7] | Ref          | Ref          | Ref          | Ref          | Ref           |     |
|                  | Q2 [3.7–4.2]       | 1.27         | 0.99–1.61    | 0.06         | 1.28         | 1.01–1.64     | 0.04|
|                  | Q3 [4.2–5.0]       | 1.05         | 0.81–1.36    | 0.69         | 1.07         | 0.82–1.38     | 0.62|
|                  | Q4 [5.0–31.2]      | 1.12         | 0.87–1.44    | 0.37         | 1.12         | 0.87–1.44     | 0.39|
|                  | Test for trend     | p = 0.68     | p = 0.71     | p = 0.68     | p = 0.71     | p = 0.71      |     |
| Linear model     | Q1 [0.6–1.6]       | 1.01         | 0.93–1.09    | 0.90         | 1.00         | 0.92–1.09     | 0.97|
| Vitamin B6       | Q1 [0.6–1.6]       | 1.01         | 0.93–1.09    | 0.88         | 1.00         | 0.92–1.09     | 0.95|
|                  | Q2 [1.6–1.9]       | 1.39         | 1.08–1.79    | 0.01         | 1.41         | 1.09–1.82     | 0.01|
|                  | Q3 [1.9–2.5]       | 1.43         | 1.11–1.85    | 0.01         | 1.47         | 1.13–1.91     | 0.00|
|                  | Q4 [2.5–30.0]      | 1.15         | 0.88–1.51    | 0.31         | 1.16         | 0.88–1.53     | 0.28|
|                  | Test for trend     | p = 0.30     | p = 0.30     | p = 0.30     | p = 0.30     | p = 0.30      |     |
| Linear model     | Q1 [0.6–1.6]       | 1.01         | 0.93–1.09    | 0.88         | 1.00         | 0.92–1.09     | 0.95|
| Biotin (B8)      | Q1 [10.8–39.6]     | 1.10         | 0.85–1.41    | 0.47         | 1.10         | 0.85–1.42     | 0.48|
|                  | Q2 [39.6–45.7]     | 1.15         | 0.89–1.50    | 0.29         | 1.16         | 0.88–1.51     | 0.29|
|                  | Q3 [45.7–52.8]     | 1.19         | 0.90–1.55    | 0.22         | 1.19         | 0.90–1.59     | 0.22|
|                  | Test for trend     | p = 0.21     | p = 0.21     | p = 0.21     | p = 0.21     | p = 0.21      |     |
| Linear model     | Q1 [10.8–39.6]     | 1.03         | 0.94–1.13    | 0.47         | 1.03         | 0.94–1.14     | 0.50|
| Folate (B9)      | Q1 [50–256]        | Ref          | Ref          | Ref          | Ref          | Ref           |     |
|                  | Q2 [256–313]       | 1.01         | 0.79–1.29    | 0.94         | 1.02         | 0.79–1.32     | 0.87|
|                  | Q3 [313–377]       | 0.97         | 0.75–1.26    | 0.83         | 0.98         | 0.75–1.28     | 0.89|
|                  | Q4 [377–1191]      | 0.99         | 0.77–1.28    | 0.95         | 1.00         | 0.76–1.32     | 1.00|
|                  | Test for trend     | p = 0.88     | p = 0.93     | p = 0.88     | p = 0.93     | p = 0.93      |     |
| Linear model     | Q1 [0.3–2.3]       | 1.00         | 0.91–1.09    | 0.95         | 1.00         | 0.91–1.10     | 1.00|
| Vitamin B12      | Q1 [0.3–2.3]       | Ref          | Ref          | Ref          | Ref          | Ref           |     |
and assimilation of B vitamins have been identified, for example, polymorphisms in ALPL with vitamin B6 and FUT2, FUT6, TCN1, TCN2, CUBN and MMAA with vitamin B12.43,44 While, at present, limited evidence exists that gene-diet interactions contribute to cancer risk,45 to our knowledge, such associations have not been assessed in the case of B vitamins and urothelial cancer.

Another limitation is that we did not have information on environmental and occupational exposures to chemicals associated with increased risk of bladder cancer (e.g., polycyclic aromatic hydrocarbons and aromatic amines), which could have confounded our estimates if exposed industry workers had unhealthier dietary habits than other cohort participants. Occupational exposure to carcinogens in Australia is estimated to cause 14% of bladder cancer in men and 0.7% in women.46 Any resulting confounding effect from differential eating habits is, therefore, likely to be very small. We adjusted our results for socioeconomic status and educational

Table 3. Associations between log-transformed intakes of B group vitamins and methionine intake with the risk of UCC (N = 500) (Continued)

| Vitamin       | Model 1 | Model 2 | Linearity p |
|---------------|---------|---------|-------------|
|               | HR 95% CI | p       | HR 95% CI  | p   | (Model 2)  |
| Q2 [2.3–3.0]  | 1.03 0.80–1.33 | 0.80 | 1.05 0.81–1.35 | 0.72 |
| Q3 [3.0–4.1]  | 1.18 0.92–1.52 | 0.19 | 1.20 0.93–1.56 | 0.15 |
| Q4 [4.1–31.9] | 0.97 0.75–1.27 | 0.85 | 1.00 0.75–1.33 | 1.00 |
| Test for trend| p = 0.87 |       | p = 0.73 |       |
| Linear model  | per 1 SD  | 1.00 0.91–1.09 | 0.94 | 1.00 0.91–1.11 | 0.95 | 0.22 |

Table 4. Associations between log-transformed intakes of B group vitamins and methionine with risk of UCC by subtypes (invasive: N = 221, superficial: N = 279)

| Vitamin       | Invasive cases (N = 221) | Superficial cases (N = 279) |
|---------------|-------------------------|-----------------------------|
|               | HR 95% CI | p | HR 95% CI | p | Linerarity p | Heterogeneity test p |
| Thiamine (B1) | 1.02 0.89–1.17 | 0.74 | 0.56 | 0.97 0.86–1.10 | 0.63 | 0.93 | 0.57 |
| Riboflavin (B2) | 1.05 0.94–1.25 | 0.26 | 0.11 | 0.95 0.84–1.08 | 0.44 | 0.11 | 0.18 |
| Niacin (B3) | 1.05 0.91–1.21 | 0.48 | 0.78 | 0.96 0.84–1.09 | 0.51 | 0.75 | 0.33 |
| Pantothenic acid (B5) | 1.05 0.93–1.18 | 0.45 | 0.05 | 0.97 0.86–1.08 | 0.53 | 0.64 | 0.52 |
| Vitamin B6 | 1.05 0.93–1.19 | 0.43 | 0.02 | 0.97 0.86–1.08 | 0.56 | 0.10 | 0.47 |
| Biotin (B8) | 1.13 0.98–1.30 | 0.10 | 0.50 | 0.96 0.84–1.10 | 0.56 | 0.83 | 0.11 |
| Folate (B9) | 1.01 0.87–1.18 | 0.85 | 0.22 | 0.99 0.87–1.13 | 0.87 | 0.46 | 0.80 |
| Vitamin B12 | 1.01 0.87–1.16 | 0.93 | 0.61 | 1.00 0.88–1.14 | 0.98 | 0.33 | 0.96 |
| Methionine | 1.00 0.86–1.16 | 0.98 | 0.48 | 1.10 0.96–1.26 | 0.15 | 0.32 | 0.33 |

1Linearity p: departure from linearity in the relationship between B-group vitamins and UCC risk was investigated in Model 2 using likelihood ratio tests to compare models with dietary intake variables as linear versus categorical (using quartiles).

2To test for heterogeneity in the HRs by tumor subtype (invasive vs. superficial), we fitted Cox proportional hazard regression models for competing risk using the data duplication method of Lunn and McNeil.46

Model 2: Adjusting for age, sex, country of birth, educational attainment, socioeconomic status, smoking status, alcohol intake, waist circumference, physical activity, MDS, red meat intake and use of NSAIDs. HRs are given per 1 SD of the log-transformed nutrient intakes.

3Heterogeneity was tested using the B vitamin variable divided into quartile, because the association with risk of invasive UCC departed from linearity (p = 0.05 and p = 0.02 for vitamin B5 and vitamin B6, respectively).
level, which provided some indirect control for occupational exposures.

The one-carbon metabolism pathway is complex and little is known about the relationship between the different B-group vitamins, and their biological interactions with other dietary and environmental exposures. 10 Even though our study population appeared to have a high daily intake of B group vitamins (Table 1), UCC is a disease that typically affects older people, and the bioavailability of these vitamins may be compromised in this demographic by certain drugs such as acid lowering agents (Proton Pump Inhibitors) and diuretics because of the water-soluble nature of this group of vitamins. 47

To our knowledge, few other studies have assessed associations between B-group vitamins and UCC risk in a systematic manner. A Danish prospective cohort study (N = 322 urothelial cancer cases) concluded that there was no association between intake of folate and risk of UCC, and their findings were also similar to ours for subgroup analyses by smoking status. 16 A Spanish case–control study of 912 bladder cancer patient cases matched with hospital-based controls, reported inverse associations of several B vitamins (B12, B6, B2 and a borderline association for folate) with UCC risk. 14 Using data from another case–control study (the New Hampshire study, N = 322 bladder cancer cases), Brinkman et al. 13 reported inverse associations with thiamine and niacin, but as in our study, no association with riboflavin, vitamin B6 and B12 or folate. Case–control studies are more prone to bias and often result in stronger risk estimates than those obtained from prospective studies. 48 A meta-analysis of the association of folate with bladder cancer risk found an inverse association in cross-sectional but not in prospective studies. 18

Table 5. Associations between log-transformed intakes of B group vitamins and methionine with risk of UCC by smoking and alcohol drinking status (Model 2)

| Vitamin     | Interaction with smoking | Interaction with alcohol drinking |
|-------------|--------------------------|-----------------------------------|
|             | HR1 95% CI               | p p het                           | HR1 95% CI               | p p het                           |
| Thiamine (B1) | Never (N = 171)          | 1.05 0.90–1.23 0.86 0.21          | Never (N = 117)          | 0.81 0.69–0.97 0.02 0.02          |
|             | Current (N = 86)         | 1.10 0.90–1.34 0.57               | Low (N = 287)            | 1.05 0.93–1.19 0.44               |
|             | Former (N = 243)         | 0.92 0.81–1.04 0.08               | High (N = 96)            | 1.12 0.92–1.36 0.27               |
| Riboflavin (B2) | Never (N = 171)          | 0.99 0.85–1.16 0.89 0.88          | Never (N = 117)          | 0.95 0.79–1.13 0.54 0.45          |
|             | Current (N = 86)         | 1.06 0.86–1.30 0.58               | Low (N = 287)            | 1.00 0.88–1.13 0.98               |
|             | Former (N = 243)         | 1.00 0.89–1.14 0.78               | High (N = 96)            | 1.12 0.92–1.35 0.25               |
| Niacin (B3)   | Never (N = 171)          | 1.02 0.87–1.19 0.59 0.87          | Never (N = 117)          | 0.96 0.80–1.14 0.63 0.77          |
|             | Current (N = 86)         | 1.03 0.84–1.28 0.99               | Low (N = 287)            | 1.03 0.91–1.17 0.67               |
|             | Former (N = 243)         | 0.97 0.85–1.12 0.27               | High (N = 96)            | 0.97 0.77–1.22 0.81               |
| Pantothenic acid (B5) | Never (N = 171)          | 0.98 0.84–1.13 0.74 0.60          | Never (N = 117)          | 1.09 0.93–1.27 0.29 0.30          |
|             | Current (N = 86)         | 1.08 0.92–1.27 0.1                | Low (N = 287)            | 0.95 0.84–1.06 0.33               |
|             | Former (N = 243)         | 0.98 0.87–1.10 0.99               | High (N = 96)            | 1.05 0.88–1.25 0.57               |
| Vitamin B6    | Never (N = 171)          | 0.98 0.85–1.14 0.81 0.94          | Never (N = 117)          | 1.08 0.93–1.26 0.33 0.48          |
|             | Current (N = 86)         | 1.03 0.86–1.22 0.33               | Low (N = 287)            | 0.99 0.89–1.11 0.85               |
|             | Former (N = 243)         | 1.00 0.89–1.13 0.82               | High (N = 96)            | 0.93 0.75–1.15 0.48               |
| Biotin (B8)   | Never (N = 171)          | 1.09 0.93–1.27 0.89 0.72          | Never (N = 117)          | 1.05 0.88–1.25 0.6 0.16           |
|             | Current (N = 86)         | 1.00 0.81–1.22 0.76               | Low (N = 287)            | 0.97 0.86–1.10 0.63               |
|             | Former (N = 243)         | 1.01 0.89–1.15 0.85               | High (N = 96)            | 1.20 0.99–1.45 0.07               |
| Folate (B9)   | Never (N = 171)          | 1.03 0.88–1.21 0.86 0.85          | Never (N = 117)          | 0.91 0.76–1.08 0.29 0.14          |
|             | Current (N = 86)         | 1.00 0.81–1.23 0.97               | Low (N = 287)            | 0.99 0.87–1.12 0.87               |
|             | Former (N = 243)         | 0.98 0.85–1.12 0.46               | High (N = 96)            | 1.18 0.96–1.44 0.11               |
| Vitamin B12   | Never (N = 171)          | 0.95 0.81–1.12 0.99 0.41          | Never (N = 117)          | 0.97 0.81–1.16 0.74 0.88          |
|             | Current (N = 86)         | 1.13 0.93–1.38 0.11               | Low (N = 287)            | 1.02 0.90–1.15 0.75               |
|             | Former (N = 243)         | 0.99 0.87–1.13 0.89               | High (N = 96)            | 1.00 0.82–1.23 1.00               |
| Methionine    | Never (N = 171)          | 0.94 0.80–1.10 0.64 0.14          | Never (N = 117)          | 0.96 0.81–1.14 0.62 0.41          |
|             | Current (N = 86)         | 1.04 0.86–1.28 0.76               | Low (N = 287)            | 1.11 0.97–1.26 0.13               |
|             | Former (N = 243)         | 1.15 1.00–1.31 0.09               | High (N = 96)            | 1.07 0.87–1.31 0.52               |

1Model 2: Adjusting for age, sex, country of birth, educational attainment, socioeconomic status, smoking status, alcohol intake, waist circumference, physical activity, MDS, red meat intake and use of NSAIDs. HRs are given per 1 SD of the log-transformed nutrient intakes. Abbreviations: het: heterogeneity.
In conclusion, our study corroborates previous research in not detecting associations between dietary intakes of B-group vitamins and the risk of UCC. Future studies on B vitamins and UCC should focus on plasma measures, investigate in more detail interactions between B vitamins and methionine regarding UCC risk and assess interactions of dietary intakes with key genetic polymorphisms involved in the one-carbon metabolism pathway.

Acknowledgements
The Melbourne Collaborative Cohort Study (MC3S) cohort recruitment was funded by the VicHealth and Cancer Council Victoria, the Australian National Health and Medical Research Council (grants 29057 and 396414), and the infrastructure is provided by Cancer Council Victoria. Cases and their vital status were ascertained through the Victorian Cancer Registry and the Australian Institute of Health and Welfare, including the National Death Index and the Australian Cancer Database.

References

1. Lopez-Beltran A. Bladder cancer: clinical and pathological profile. Scand J Urol Nephrol Suppl 2008;42:95–109.
2. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011;61:69–90.
3. Burger M, Casto JW, Dalbaghi G, et al. Epidemiology and risk factors of urothelial bladder can-
cer. Eur Urol 2013;63:234–41.
4. Dugue PA, Hodge AM, Brinkman MT, et al. Association between selected dietary scores and the risk of urothelial cell carcinoma: a prospective cohort study. Int J Food Sci Nutr 2014;65:286–92.
5. Braver DJ, Modan M, Chetrit A, et al. Drinking, mins and the risk of UCC. Future studies on B vitamins and methionine and risk of UCC should focus on plasma measures, investigate in more detail interactions between B vitamins and methionine regarding UCC risk and assess interactions of dietary intakes with key genetic polymorphisms involved in the one-carbon metabolism pathway.
6. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011;61:69–90.
7. Brinkman MT, Karagas MR, Zens MS, et al. Min-
8. World Cancer Research Fund International/ American Institute for Cancer Research. Food, nutrition, physical activity, and the prevention of cancer: a global perspective, Washington, DC, USA: American Institute for Cancer Research, 2007.
9. Norat NV, AR, Aune D, et al. World Cancer Research Fund International/American Institute for Cancer Research. Continuous Update Project Report. Diet, Nutrition, Physical Activity and Bladder Cancer. 2015. https://www.wcrf.org/sites/default/files/Bladder-Cancer-2015-Report.pdf
10. Kile ML, Ronnenberg AG. Can folate intake reduce arsenic toxicity? Nutr Rev 2008;66:34–53.
11. Anderson OS, Satt KE, Dukony DC. Nutrition and epigenetics: an interplay of dietary methyl donors, one-carbon metabolism and DNA methylation. J Nutr Biochem 2012;23:853–9.
12. Locasale JW. Serine, glycine and one-carbon units: cancer metabolism in full circle. Nat Rev Cancer 2013;13:572–83.
13. Esteller M. Epigenetics in cancer. N Engl J Med 2008;358:1148–59.
14. Dugue PA, Brinkman MT, Milne RL, et al. Geno-
15. Esteller M. Epigenetics in cancer. N Engl J Med 2008;358:1148–59.
16. Roswall N, Olsen A, Christensen J, et al. Micronu-
17. Schabath MB, Spitz MR, Lerner SP, et al. Case-
18. He H, Shui B. Folate intake and risk of bladder cancer: a meta-analysis of epidemiological studies. Int J Food Sci Nutr 2014;65:286–92.
19. Wu JW, Cross AJ, Baris D, et al. Dietary intake of meat, fruits, vegetables, and selective micronu-
trients and risk of bladder cancer in the New England region of the United States. Br J Cancer 2012;106:1891–8.
20. Milne RL, Hetzel AS, MacInnis RJ, et al. Cohort profile: the Melbourne Collaborative Cohort Study (Health 2020). Int J Epidemiol 2017;46:1757–7571.
21. Aine M, Eriksson P, Liedberg F, Hoglund M, Sjodahl G. On molecular classification of bladder cancer: out of one, many. Eur Urol 2015;68:921–3.
22. Ireland P, Jolley D, Giles G, et al. Development of the Melbourne FFQ: a food frequency ques-
tionnaire for use in an Australian prospective study involving an ethnically diverse cohort. Asia Pacific J Clin Nutr 1994;3:19–31.
23. Food Standards Australia New Zealand (FSANZ). NUTTAB 2010, vol. 2017, 2011. Available at: https://www.foodstandards.gov.au/science/ monitoringnutrients/nutritionaltables/nuttab/DOCS/REVISED%20Complete%20Explatory%20Notes%20with%2040Attachments%20may%202011.pdf. Last accessed 15 December 2017.
24. Bassett JK, Baglietto L, Hodge AM, et al. Dietary intake of B vitamins and methionine and breast cancer risk. Cancer Causes Control 2013;24:1555–63.
25. Bassett JK, Hodge AM, English DR, et al. Dietary intake of B vitamins and methionine and risk of lung cancer. Eur J Clin Nutr 2012;66:182–7.
26. Bassett JK, Severi G, Hodge AM, et al. Dietary intake of B vitamins and methionine and prostate cancer incidence and mortality. Cancer Causes Control 2012;23:855–63.
27. Bassett JK, Severi G, Hodge AM, et al. Dietary intake of B vitamins and methionine and colorec-
tal cancer risk. Nutr Cancer 2013;65:659–67.
28. Willett W, Stampfer MJ. Total energy intake: implications for epidemiologic analyses. Am J Epidemiol 1986;124:17–27.
29. Pink B. Socio-economic indexes for areas (SEIFA). Canberra: Australian Bureau of Statis-
tics, 2013.
30. MacInnis RJ, English DR, Hopper JL, et al. Body size and composition and colon cancer risk in men. Cancer Epidemiol Biomarkers Prev 2004;13:553–9.
31. Thibault AC, Benichou J. Choice of time-scale in Cox’s model analysis of epidemiologic cohort data: a simulation study. Stat Med 2002;23:3803–20.
32. Grambsch PM, Therneau TM. Proportional haz-
ard tests and diagnostics based on weighted residuals. Biometrika 1994;81:515–26.
33. Rothman KJ, Greenland S, Lash TL. Modern epide-
miology. Lippincott Williams & Wilkins, 2008.
34. Lunn M, McNeil D. Applying Cox regression to competing risks. Biometrics 1995;51:324–32.
35. Latt N, Dore G. Thiamine in the treatment of Wernicke encephalopathy in patients with alcohol use disorders. Intern Med J 2014;44:911–5.
36. Day E, Beatham PW, Callaghan R, et al. Thia-
mine for prevention and treatment of Wernicke-Korsakoff Syndrome in people who abuse alcohol. Cochrane Database Syst Rev 2013; CD004033.
37. Bassett JK, English DR, Fehay MT, et al. Validity and calibration of the FFQ used in the Mel-
bourne Collaborative Cohort Study. Public Health Nutr 2016;19:2357–68.
38. Armstrong BKWE, Saracci R. Principles of expo-
sure measurement in epidemiology. Oxford: Oxford University Press, 1992.
39. Hicking S, Hung J, Knuijnen M, et al. Impact of volun-
tary folate fortification on plasma homocys-
teine and serum folate in Australia from 1995 to 2001: a population based cohort study. J Epidemiol Community Health 2005;59:371–6.
40. Kammie M. The repeating history of objections to the fortification of bread and alcohol from iron filings to folic acid. Med J Aust 2006;184:638–40.
41. de Batte J, Matejec M, Chajes V, et al. Determinants of folate and vitamin B12 plasma levels in the French EIN-EPIC cohort. Eur J Nutr 2016. doi: 10.1007/s00094-016-3657-9. [Epub ahead of print]
42. de Bree A, Verschuren WM, Bjerke-Monsen AL, et al. Effect of the methyltetrahydrofolate reductase 677C>T mutation on the relations among folate intake and plasma folate and homocys-
teine concentrations in a general population sample. Am J Clin Nutr 2003;77:687–93.
43. Nongnaiwath SS, Joglekar CV, Krishnaveni GV, et al. GWAS identifies population-specific new regulatory variants in FUT6 associated with plasma B12 concentrations in Indians. Human Mol Genet 2017;26:2551–64.
44. Tanaka T, Scheet P, Giunti B, et al. Genome-wide association study of vitamin B6, vitamin B12, folate, and homocysteine blood concentrations. Am J Human Genomics 2009;84:477–82.
45. Theodoratou E, Timofeeva M, Li X, et al. Nature, nurture, and cancer risks: genetic and nutritional contributions to cancer. Annu Rev Nutr 2017;37:293–320.
46. Fritschi L, Driscoll T. Cancer due to occupation in Australia. Aust N Z J Public Health 2006;30:213–9.
47. Suter PM, Vetter W. Diuretics and vitamin B1: are diuretics a risk factor for thiamin malnutri-
tion? Nutr Rev 2000;58:319–23.
48. Riboli E, Norat T. Epidemiologic evidence of the protective effect of fruit and vegetables on cancer risk. Am J Clin Nutr 2003;78:5595–695.